Several studies have investigated the prevalence of germline TP53 mutations in non-Brazilian BC patients selected or not selected for a FHC, providing evidence that germline TP53 mutations are associated with a fraction of early BC diagnoses irrespective of a FHC [4], [5], [28], [29]. Here, TP53 is linked to breast cancer.